Lv51
1060 积分 2023-06-12 加入
An immunomechanical checkpoint PYK2 governs monocyte-to-macrophage differentiation in pancreatic cancer
4小时前
已完结
An immunomechanical checkpoint PYK2 governs monocyte-to-macrophage differentiation in pancreatic cancer
5小时前
已关闭
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
16天前
已完结
Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat
27天前
已关闭
Neoadjuvant treatment of HER2-positive breast cancer: has the era of antibody–drug conjugates arrived?
1个月前
已完结
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
1个月前
已完结
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study
1个月前
已完结
Immunotherapy plus tyrosine-kinase inhibitors in hepatocellular carcinoma
1个月前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
1个月前
已完结
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study
1个月前
已关闭
皖公网安备34019202002308
